Stem Cell Transplant: Considering a Potential Cure

An allogeneic hematopoietic stem cell transplant (allo-HSCT) is currently the only treatment that offers a potential cure for myelofibrosis ^[1][2]. Unlike other treatments that manage symptoms, a transplant replaces your diseased bone marrow with healthy stem cells from a donor ^[3]. However, because it is an intensive procedure with significant risks, it is typically reserved for patients whose disease is likely to progress without it ^[4]. An early transplant consultation can allow donor evaluation without obligating you to proceed.

Who is a Candidate for Transplant?

Deciding when to proceed with a transplant involves balancing the risks of the procedure against the risks of the myelofibrosis itself. National and international guidelines (such as NCCN and EBMT/ELN) generally recommend considering a transplant for:

• Higher-Risk Disease: Patients classified as “Intermediate-2” or “High” risk by clinical scoring systems like DIPSS or MIPSS70 ^[3][4].
• Selected Intermediate-1 Disease: Patients who may have lower clinical risk but have “concerning” features, such as needing frequent blood transfusions, having a circulating blood blast level of 2% or more (which is not necessarily “accelerated phase” but can be an adverse transplant feature), or carrying high-risk genetic mutations ^[3].
• Secondary Myelofibrosis: Patients whose MF developed from Polycythemia Vera or Essential Thrombocythemia are often evaluated using the MYSEC-PM score to determine if a transplant is appropriate ^[5].

Your doctor will also use the MTSS (Myelofibrosis Transplant Scoring System), which looks at your age, donor type, physical fitness, leukocyte count, platelet count, and genetic mutations to predict how well you might tolerate the procedure ^[6].

Preparing the Body: Spleen Reduction

Before the transplant begins, it is often critical to reduce the size of an enlarged spleen. A massive spleen is associated with delayed engraftment and poorer transplant outcomes, which may lead to graft failure (where the new cells fail to grow) or slow the recovery of your blood counts ^[7][8].

Spleen reduction is individualized by your transplant center and is usually achieved through:

• JAK Inhibitors: Drugs like ruxolitinib are often used for several months before transplant to shrink the spleen and reduce inflammation ^[3][9].
• Splenic Irradiation: If medications don’t work, low-dose radiation can be used to shrink the spleen shortly before the transplant ^[10].
• Splenectomy: In rare, severe cases, the spleen may be surgically removed, though this carries higher surgical risks for MF patients ^[11].

The Transplant Process and Conditioning

The process begins with conditioning, which is a period of chemotherapy (and sometimes radiation) designed to clear out your diseased marrow and “quiet” your immune system so it accepts the donor cells ^[3].

There are two main types of conditioning:

1. Myeloablative Conditioning (MAC): Uses high doses of chemotherapy. It is very effective at clearing the disease but is physically taxing and generally reserved for younger, fit patients ^[3].
2. Reduced-Intensity Conditioning (RIC): Uses lower doses of chemotherapy. It relies more on the “graft-versus-myelofibrosis” effect, where the donor’s immune cells attack the remaining MF cells. This is often the preferred choice for older patients or those with other health concerns ^[12][3].

Monitoring for Success: The Role of Driver Mutations

After the transplant, your care team will monitor you closely for minimal residual disease (MRD). This involves testing your blood or marrow for the same “driver” mutations you had at diagnosis (JAK2, CALR, or MPL) ^[3]. Patients with triple-negative disease cannot be followed using this specific test.

The goal is for these mutations to disappear entirely, which is known as molecular remission ^[13]. If these mutations are still detectable 100 or 180 days after the transplant, it may be an early risk signal that the disease could return ^[13]. This is not an automatic diagnosis of relapse and must be interpreted alongside your blood counts, marrow findings, and donor chimerism. Detecting these signals early allows doctors to adjust your medications or provide donor cells (donor lymphocyte infusion), though this intervention itself carries risks of graft-versus-host disease ^[3].

Substantial Risks to Consider

While potentially curative, allo-HSCT carries significant, life-altering risks, including Graft-versus-Host Disease (GVHD)—where the donor cells attack your healthy tissues—and a period of high vulnerability to infections ^[14][15]. Additional risks include graft failure, relapse, organ toxicity, infertility or early menopause, and treatment-related mortality. Your transplant team will discuss these risks, as well as fertility preservation options, in detail to help you make an informed decision ^[16].